fm
munoz
see
front
matter
publish
elsevi
scienc
bv
pii
fm
munoz
et
al
second
intern
symposium
influenza
respiratori
virus
conven
macra
group
new
york
citi
ny
grand
cayman
cayman
island
decemb
summari
first
intern
symposium
publish
journal
antivir
research
kaiser
et
al
purpos
second
symposium
reunit
lead
expert
around
world
review
recent
develop
research
influenza
respiratori
syncyti
respiratori
virus
provid
new
insight
epidemiolog
clinic
impact
detect
pathogenesi
manag
novel
approach
immun
antivir
treatment
emphas
meet
intend
benefit
work
field
provid
multidisciplinari
forum
open
discuss
among
repres
academia
govern
industri
meet
chair
frederick
g
hayden
univers
virginia
usa
robert
b
couch
baylor
colleg
medicin
usa
attend
particip
countri
invit
speaker
includ
goran
wadel
univers
hospit
umea
sweden
per
ljungman
hudding
hospit
sweden
mari
griffin
vanderbilt
univers
school
medicin
nashvil
tn
usa
robert
webster
st
jude
type
influenza
viru
rna
viru
neg
sens
segment
genom
exist
quasi
speci
proof
read
mechan
prone
mutat
replic
properti
make
highli
variabl
viru
undergo
continu
antigen
drift
minor
antigen
variat
infrequ
antigen
shift
major
antigen
variat
fifteen
hemagglutinin
nine
neuraminidas
subtyp
antigen
influenza
viru
recogn
natur
subtyp
antigen
occur
wild
bird
reservoir
particularli
duck
shorebird
two
clade
anim
influenza
virus
eurasian
american
highli
transmiss
influenza
strain
result
signific
morbid
high
fever
fetal
abort
variabl
mortal
appear
swine
us
two
genet
distinct
swine
viru
variant
identifi
zhou
et
al
one
doubl
reassort
origin
human
pig
strain
second
tripl
reassort
protein
deriv
human
ha
na
swine
np
ns
american
avian
pa
strain
latter
viru
current
widespread
pig
rais
region
us
could
potenti
reinfect
human
virus
chicken
reservoir
also
undergo
import
chang
itali
preval
previous
innocu
variant
began
caus
diseas
chicken
anoth
subtyp
viru
appear
hong
kong
poultri
market
human
caus
respiratori
diseas
human
sever
enough
result
death
six
person
infect
sinc
implement
major
measur
control
includ
slaughter
poultri
extens
clean
market
viru
detect
hong
kong
viru
emerg
china
caus
increas
morbid
mortal
chicken
decreas
egg
product
anoth
lineag
detect
two
children
respiratori
diseas
indistinguish
aquailhong
virus
compris
onethird
influenza
virus
isol
poultri
market
hong
kong
viru
contain
genet
segment
similar
viru
provid
potenti
viru
transmit
human
guan
et
al
influenza
b
viru
known
anim
reservoir
howev
variant
influenza
b
viru
recent
isol
throat
swab
harbor
seal
phoca
respiratori
symptom
admit
rehabilit
research
center
pieterburen
netherland
serolog
evid
infect
igm
igg
hemagglutinininhibit
antibodi
document
anoth
contact
anim
genet
sequenc
viru
homolog
human
epidem
influenza
b
strain
circul
addit
serolog
evid
influenza
b
infect
document
eight
seal
sampl
although
mechan
transmiss
remain
unknown
first
time
human
influenza
b
viru
found
caus
natur
infect
anim
speci
capac
seal
reservoir
influenza
virus
remain
determin
interspeci
transmiss
influenza
virus
occur
year
chimer
virus
appear
occur
frequent
whether
repres
increas
occurr
increas
recognit
certain
contribut
factor
increas
occurr
includ
increas
anim
human
popul
opportun
interact
concern
potenti
increas
interspeci
transmiss
could
rais
possibl
emerg
new
pandem
strain
human
influenza
epidem
houston
tx
influenza
diagnos
cultur
enzym
immunoassay
eia
children
upper
lower
respiratori
tract
symptom
influenza
influenza
b
children
year
age
particularli
year
age
highest
rate
hospit
acut
respiratori
diseas
laboratori
confirm
influenza
children
underli
condit
place
high
risk
complic
influenza
experienc
greater
morbid
frequent
hospit
howev
hospit
children
risk
factor
year
age
children
like
develop
lower
respiratori
tract
diseas
otiti
media
febril
ill
complic
febril
seizur
gastroenter
dehydr
vaccin
rate
low
b
high
risk
children
nil
previous
healthi
children
influenza
epidem
increas
death
rate
among
elderli
studi
respiratori
infect
elderli
stockholm
sweden
influenza
found
predomin
pathogen
januari
june
respiratori
sampl
obtain
ill
patient
year
age
older
viral
pathogen
includ
influenza
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
impact
influenza
also
shown
import
long
term
care
facil
ontario
canada
long
term
care
facil
experienc
outbreak
respiratori
diseas
juli
june
due
influenza
alon
rsv
alon
influenza
rsv
piv
rhinoviru
rv
agent
facil
higher
influenza
vaccin
rate
staff
report
fewer
outbreak
current
possibl
accur
predict
time
appear
next
influenza
pandem
thu
plan
pandem
process
involv
develop
strategi
build
expertis
infrastructur
deal
unpredict
perhap
catastroph
event
anticip
past
experi
possibl
unexpect
consequ
certain
strategi
intervent
plan
accomplish
two
object
effect
assess
pandem
risk
defin
role
possibl
action
variou
medic
public
health
institut
pandem
prepared
address
panel
expert
role
maintain
global
influenza
surveil
network
facilit
detect
novel
influenza
virus
interpandem
period
declar
onset
end
pandem
signific
collabor
worldwid
necessari
accomplish
nation
health
author
countri
establish
pandem
plan
committe
decis
make
regard
surveil
scientif
medic
issu
suppli
distribut
antivir
drug
manag
pandem
take
consider
commun
legal
polit
econom
issu
jid
countri
make
best
use
avail
resourc
reduc
impact
diseas
manag
exposur
approach
prevent
pandem
possibl
current
high
level
intern
travel
expans
popul
mani
region
world
purpos
influenza
surveil
includ
know
influenza
virus
circul
determin
impact
influenza
activ
detect
unusu
event
emerg
pandem
strain
assist
diseas
control
surveillancebas
recommend
determin
effect
control
measur
earli
detect
new
influenza
strain
crucial
rapid
respons
pandem
threat
recent
influenza
pandem
gap
sever
month
occur
time
widespread
outbreak
influenza
occur
time
viru
first
isol
true
pandem
pandem
viru
mani
surveil
lesson
learn
experi
outbreak
snacken
et
al
case
network
identifi
singl
isol
earli
process
allow
local
prepar
need
better
surveil
asia
particularli
china
appar
learn
difficult
enhanc
global
even
nation
surveil
great
need
expand
influenza
surveil
anim
learn
influenza
virus
jump
host
speci
barrier
without
reassort
need
increas
avail
biosafeti
level
contain
facil
worldwid
studi
highli
virul
virus
need
train
surveil
becam
obviou
well
mani
countri
fund
influenza
surveil
limit
new
innov
mechan
need
place
provid
fund
surveil
conting
plan
enhanc
global
surveil
pandem
alert
need
develop
expans
influenza
surveil
china
pacif
basin
countri
necessari
intervent
control
pandem
influenza
consid
three
level
prevent
popul
becom
infect
limit
least
slow
progress
epidem
deal
consequ
infect
elimin
sourc
occur
slaughter
poultri
outbreak
hong
kong
unlik
achiev
viru
transmit
effici
person
person
option
slow
spread
includ
use
antivir
prophylaxi
limit
congreg
peopl
possibl
quarantin
antivir
prophylaxi
best
approach
present
time
need
adequ
suppli
larg
popul
mani
week
provid
effect
vaccin
princip
focu
pandem
plan
cox
fukuda
practic
issu
consid
includ
provid
vaccin
suppli
quickli
optim
use
avail
dose
often
delay
prepar
vaccin
time
viru
first
identifi
time
vaccin
readi
distribut
plan
consid
distribut
candid
vaccin
mani
nation
plan
list
vaccin
intervent
plan
obtain
candid
viru
subtyp
prepar
advanc
vaccin
product
could
shorten
week
compar
normal
week
process
nevertheless
major
question
answer
much
antigen
variat
within
subtyp
current
viru
subtyp
strain
repres
candid
much
cover
cost
prepar
candid
vaccin
would
select
variant
stock
pile
vaccin
prepar
sinc
world
popul
would
larg
suscept
new
subtyp
one
possibl
would
use
antigen
similar
avail
strain
obtain
degre
immunolog
prime
within
subtyp
decreas
sever
diseas
immun
individu
altern
mechan
would
use
recombin
live
attenu
virus
may
induc
broader
spectrum
immun
respons
inactiv
vaccin
time
possibl
prepar
variou
subtyp
reagent
know
might
use
sinc
last
pandem
method
prepar
vaccin
chang
limit
comparison
respons
observ
previou
studi
split
viru
vaccin
made
instead
whole
viru
vaccin
respons
may
differ
howev
increas
product
capac
amount
protect
confer
differ
vaccin
minimum
effect
dose
protect
need
consid
option
includ
give
one
dose
entir
popul
two
dose
half
popul
assum
enough
dose
achiev
new
jersey
outbreak
children
viru
better
respons
whole
viru
split
viru
vaccin
two
dose
whole
viru
vaccin
need
achiev
protect
level
antibodi
cell
cultur
base
vaccin
consid
investig
number
year
yet
enter
gener
use
advantag
mdck
cell
grow
suspens
disadvantag
cell
vero
vaccin
product
requir
growth
adapt
serum
free
condit
addit
trypsin
effici
replic
although
approv
vaccin
grown
vero
cell
polio
prefer
cell
influenza
would
probabl
mdck
cell
would
undergo
regulatori
consider
determin
presenc
adventiti
virus
prion
nucleic
acid
issu
consid
product
capac
cell
line
econom
issu
use
sourc
develop
time
egg
grown
vaccin
potenti
scalabl
altern
vaccin
consid
live
attenu
vaccin
requir
approxim
product
time
inactiv
vaccin
longer
need
establish
safeti
possibl
dose
rang
studi
moreov
requir
special
pathogen
free
egg
limit
suppli
genet
engin
hemagglutinin
gave
poor
result
subtyp
human
dose
mg
dna
vaccin
addit
adjuv
vaccin
option
futur
first
line
defens
pandem
vaccin
antivir
drug
altern
amantadin
rimantadin
approv
treatment
prophylaxi
influenza
effect
pandem
influenza
proven
earlier
trial
new
class
antivir
agent
activ
influenza
b
becam
avail
neuraminidas
inhibitor
ni
zanamavir
relenza
glaxo
oseltamivir
tamiflu
roch
approv
use
variou
countri
europ
north
south
america
util
drug
pandem
need
consid
current
antivir
drug
us
avail
limit
number
dose
less
million
dose
would
rapidli
deplet
case
pandem
indic
earlier
prophylaxi
larg
number
peopl
option
one
patient
current
receiv
antivir
drug
treatment
influenza
less
million
prescript
written
influenza
season
assess
potenti
contribut
antivir
current
futur
product
capac
purchas
distribut
logist
fund
need
determin
manufactur
process
timelin
step
rate
limit
stage
product
howev
potenti
stockpil
drug
exist
current
recommend
antivir
use
anim
influenza
includ
pig
hors
chicken
potenti
induct
resist
pandem
strain
option
need
discuss
involv
swine
poultri
product
coordin
longitudin
anim
human
studi
need
learn
virus
circul
anim
popul
frequenc
transmit
human
properti
transmit
virus
antivir
intervent
anim
might
reduc
risk
gener
new
pandem
viru
us
current
option
optim
use
exist
antivir
pandem
includ
govern
purchas
drug
high
risk
group
use
exist
suppli
prophylaxi
treatment
high
risk
group
sever
ill
patient
earli
treatment
offer
benefit
increas
chanc
therapeut
success
reduct
complic
interfer
immun
potenti
decreas
viral
transmiss
therefor
import
consid
develop
strategi
product
prioriti
distribut
class
antivir
drug
niaid
conven
intern
workshop
consid
influenza
pandem
prepared
identifi
critic
gap
issu
jid
recommend
develop
pandem
plan
committe
includ
expand
surveil
develop
librari
highgrowth
reassort
differ
influenza
subtyp
produc
clinic
test
pilot
lot
vaccin
avian
strain
pandem
potenti
establish
cell
cultur
system
product
influenza
vaccin
increas
collabor
among
intern
laboratori
share
inform
reagent
strain
new
technolog
advanc
train
laboratori
clinic
research
one
main
goal
set
workshop
improv
intern
surveil
effort
emphasi
anim
surveil
multiyear
contract
award
st
jude
research
hospit
work
issu
addit
surveil
identif
isol
virus
could
made
avail
commun
becom
import
vaccin
develop
anoth
goal
prepar
complement
refer
reagent
identifi
work
new
hemagglutinin
ha
neuraminidas
na
subtyp
purifi
protein
monoclon
antibodi
sheep
antisera
prepar
new
protein
sheep
antiserum
soon
avail
use
cold
adapt
trival
influenza
vaccin
children
alter
cours
outbreak
current
evalu
texa
investig
baylor
colleg
medicin
support
provid
clinic
trial
includ
purifi
na
supplement
inactiv
vaccin
improv
understand
role
humor
cellular
mucos
immun
protect
influenza
stimul
develop
seri
investig
initi
research
grant
niaid
also
support
basic
biolog
molecular
epidemiolog
pathogenesi
influenza
well
research
adjuv
novel
deliveri
system
assess
true
impact
respiratori
virus
transplant
patient
difficult
due
lack
control
studi
current
report
repres
data
select
popul
particularli
suffer
sever
infect
therefor
causal
relationship
viral
infect
outcom
clearli
determin
prospect
studi
bone
marrow
transplant
bmt
recipi
european
center
incid
respiratori
viral
infect
allogen
stem
cell
transplant
stc
recipi
higher
frequenc
rang
autolog
stc
recipi
rang
outcom
respiratori
viru
infect
howev
similar
group
surviv
respect
rsv
caus
seriou
diseas
bmt
recipi
upper
respiratori
tract
infect
urti
progress
pneumonia
patient
surviv
rsv
urti
approxim
decreas
pneumonia
develop
infect
occur
earli
within
month
late
transplant
late
infect
begin
mild
urti
commonli
progress
obstruct
bronchiol
chronic
oxygen
depend
worsen
respiratori
symptom
respiratori
insuffici
continu
even
rsv
clear
respiratori
tract
time
highest
risk
infect
rsv
bmt
patient
variabl
accord
studi
md
anderson
hospit
texa
period
neutropenia
earli
phase
rsv
urti
progress
pneumonia
occur
rare
engraft
whimbey
et
al
recent
european
studi
neutropenia
risk
factor
progress
lower
respiratori
tract
diseas
older
age
lymphopenia
unrel
hla
mismatch
bmt
recipi
higher
risk
develop
rsv
pneumonia
anecdot
treatment
regimen
rsv
diseas
bmt
patient
popul
includ
administr
ribavirin
alon
combin
immunoglobulin
g
igg
although
treatment
combin
remain
investig
appear
provid
benefit
rout
administr
ribavirin
also
studi
europ
treatment
combin
intraven
iv
inhal
ih
ribavirin
without
igg
result
improv
surviv
affect
patient
compar
treat
iv
ih
ribavirin
alon
combin
igg
mechan
potenti
effect
optim
rout
administr
still
need
defin
monoclon
antibodi
rsv
treatment
patient
pneumonia
studi
small
group
patient
high
risk
patient
surviv
parainfluenza
viru
infect
detect
bmt
recipi
texa
lewi
et
al
group
patient
piv
develop
pneumonia
die
overal
mortal
piv
also
caus
sever
diseas
patient
receiv
transplant
unrel
mismatch
donor
independ
caus
death
allogen
stem
cell
transplant
recipi
european
studi
piv
respiratori
tract
infect
bmt
patient
result
mortal
high
treatment
regimen
includ
iv
ih
ribavirin
howev
small
number
subject
report
number
piv
serotyp
limit
interpret
data
influenza
viru
infect
bmt
recipi
frequent
caus
interstiti
pneumonia
associ
rate
mortal
approxim
overal
whimbey
et
al
european
studi
overal
surviv
document
period
greatest
risk
develop
pneumonia
year
transplant
treatment
amantadin
rimantadin
use
data
efficaci
patient
popul
bmt
recipi
poor
respons
influenza
vaccin
attempt
improv
respons
administr
granulocyt
monocyt
coloni
stimul
factor
result
addit
benefit
allogen
bmt
recipi
autolog
bmt
recipi
hematolog
malign
improv
respons
breast
cancer
patient
occur
given
less
month
transplant
rhinoviru
associ
fatal
pneumonia
ard
transplant
patient
ghosh
et
al
european
studi
five
death
occur
patient
diagnos
rv
infect
causeeffect
relationship
found
data
would
support
associ
rv
infect
sever
outcom
bmt
recipi
time
three
studi
summar
support
hypothesi
human
immunodefici
viru
hiv
infect
patient
frequent
andor
sever
infect
due
respiratori
virus
one
small
trial
inactiv
influenza
viru
vaccin
demonstr
good
efficaci
data
lack
burden
diseas
efficaci
immun
level
immunodefici
infant
month
age
enrol
prospect
cohort
studi
follow
year
develop
febril
upper
lower
respiratori
tract
infect
king
et
al
hivinfect
children
higher
rate
endpoint
per
personyear
respect
match
children
without
hiv
infect
per
personyear
document
viral
infect
account
ill
rsv
isol
rsvinfect
children
hiv
prolong
rsv
viral
shed
frequent
pneumonia
less
frequent
bronchiol
children
without
hiv
infect
signific
increas
death
pneumonia
influenza
p
among
person
age
note
us
begin
investig
phenomenon
reveal
increas
greatest
citi
higher
incid
aid
addit
p
mortal
rate
peak
winter
month
suggest
role
influenza
andor
respiratori
virus
retrospect
cohort
studi
women
age
million
personyear
enrol
tennesse
medicaid
program
report
hivinfect
women
risk
influenzaattribut
hospit
least
high
women
high
risk
medic
condit
neuzil
et
al
howev
estim
ci
acut
cardiopulmonari
hospit
per
hivinfect
women
base
rel
small
number
person
year
respons
hiv
infect
patient
influenza
vaccin
studi
group
hiv
infect
militari
recruit
influenza
season
tasker
et
al
poor
respons
vaccin
observ
despit
lack
advanc
hiv
diseas
nevertheless
vaccin
efficaci
influenza
urti
good
vaccin
recruit
report
urti
versu
placebo
recipi
suggest
ill
prevent
vaccin
recipi
influenza
viru
isol
five
placebo
recipi
zero
eight
symptomat
immun
individu
provid
vaccin
efficaci
influenza
infect
rang
influenza
viru
pandem
kill
million
peopl
period
year
first
wave
pandem
report
earli
march
present
simultan
far
east
europ
us
summer
month
viru
ravag
troop
europ
side
front
fall
earli
part
explod
virul
second
wave
contin
conserv
estim
attribut
million
death
influenza
recent
estim
closer
million
us
excess
death
total
death
philadelphia
death
occur
octob
us
militari
total
troop
casualti
world
war
attribut
influenza
life
expect
us
centuri
precipit
drop
year
drop
occur
unusu
age
adjust
mortal
uniqu
peak
year
age
group
importantli
peopl
influenza
cours
fever
improv
die
main
caus
secondari
bacteri
pneumonia
subset
victim
usual
young
adult
die
rapidli
sometim
within
h
onset
exhibit
distinct
patholog
character
massiv
pulmonari
edema
hemorrhag
also
seen
small
percentag
patient
pandem
frequent
goal
project
seek
sequenc
viru
determin
viru
came
went
virul
rna
recov
lung
tissu
victim
pandem
first
case
healthi
soldier
fort
jackson
south
carolina
day
cours
influenza
begin
peak
second
wave
die
septemb
massiv
bacteri
pneumonia
left
lung
second
case
healthi
male
influenza
septemb
armi
camp
new
york
die
massiv
pulmonari
edema
ill
third
case
repres
lung
tissu
exhum
frozen
bodi
inuit
femal
age
unknown
die
influenza
novemb
northern
alaska
histolog
show
massiv
acut
pulmonari
hemorrhag
fragment
rna
found
specimen
small
piec
base
length
repres
entir
genom
hemagglutinin
ha
gene
sequenc
sequenc
basic
amino
acid
cleavag
site
character
virul
avian
virus
structur
four
potenti
glycosyl
site
found
occur
consensu
avian
sequenc
none
addit
glycosyl
site
seen
frequent
human
sequenc
antigen
site
predominantli
avian
consensu
sequenc
receptor
bind
site
three
case
two
nucleotid
differ
sequenc
one
synonym
chang
one
nonsynonym
chang
receptor
bind
site
new
york
case
glycin
residu
would
give
receptor
bind
profil
similar
european
swine
virus
possibl
abil
bind
alaskan
south
carolina
case
aspart
acid
site
phylogenet
viru
mammalian
viru
repres
outgroup
avian
sequenc
distinct
pattern
seen
virus
novel
ha
clearli
avian
structur
viru
bind
site
glycosyl
site
avian
consensu
suggest
ha
avian
underw
mammalian
adapt
viru
well
adapt
human
sinc
infecti
highli
transmiss
replic
high
copi
number
lung
two
possibl
origin
viru
one
sequenc
viru
deriv
reassort
event
bird
ha
sequenc
modif
avian
sequenc
drift
last
year
previous
thought
therefor
avian
sequenc
would
expect
differ
modern
avian
sequenc
within
domain
nearest
avian
sequenc
viru
differ
amino
acid
nearest
avian
sequenc
differ
nine
one
two
amino
acid
drift
avian
year
could
occur
could
avian
sourc
littl
modif
repres
avianlik
viru
longer
avail
possibl
avian
ancestor
pandem
viru
adapt
mammal
period
time
estim
appear
viru
around
viru
sequenc
neuraminidas
na
gene
open
read
frame
base
seven
glycosyl
site
characterist
avian
sequenc
antigen
site
identifi
antigen
site
map
seven
site
avian
mammalian
sequenc
vari
viru
site
match
avian
consensu
activ
site
na
complet
conserv
seen
influenza
virus
phylogenet
analysi
na
show
sequenc
divid
avian
mammalian
clade
sequenc
close
sequenc
common
ancestor
human
classic
swine
origin
near
root
mammalian
clade
like
ha
structur
mani
avian
featur
phylogenet
within
mammalian
clade
phylogenet
also
come
root
human
swine
ns
sequenc
postul
viru
increas
virul
possibl
pantrop
neurotrop
viru
loss
glycosyl
site
residu
avianlik
cleavag
site
mutat
ha
delta
mutat
na
structur
featur
suggest
behav
pantrop
manner
enceph
lethargica
von
economo
neurolog
complic
seen
time
influenza
first
describ
austrian
neuropathologist
constantin
von
economo
patient
seen
clinic
vienna
therefor
first
case
occur
outbreak
spanish
influenza
case
met
descript
enceph
lethargica
taper
disappear
period
million
case
postul
relat
influenza
pandem
neurotrop
viru
clinic
cours
vari
constel
symptom
includ
acut
enceph
without
death
develop
postencephalit
parkinson
diseas
year
later
archiv
arm
forc
institut
patholog
review
evid
case
enceph
lethargica
five
case
acut
death
cours
identifi
post
encephalit
parkinson
case
clinic
occurr
decad
onset
symptom
brain
block
avail
rna
lysat
made
none
sampl
posit
influenza
rna
matrix
nucleoprotein
therefor
acut
enceph
lethargica
death
good
represent
midbrain
nuclei
influenza
rna
recov
howev
sampl
four
coal
miner
die
spitsbergen
report
contain
viru
rna
brain
respiratori
tissu
signific
find
known
issu
pantrop
confirm
examin
multipl
specimen
victim
influenza
pandem
us
possibl
treat
influenza
increas
demand
virolog
diagnosi
clinician
vari
abil
recogn
influenza
base
clinic
manifest
alon
abil
depend
part
feedback
receiv
laboratori
use
diagnost
test
test
current
avail
point
care
rapid
kit
antigen
detect
test
sensit
specif
accord
manufactur
variat
partli
depend
refer
method
use
evalu
factor
includ
age
patient
type
sampl
time
sampl
collect
rel
onset
ill
consequ
poor
specif
fals
posit
wors
fals
neg
result
moreov
spuriou
interpret
impair
correct
label
epidem
lead
misdiagnosi
anoth
seriou
infect
ideal
specif
greater
aspect
rapid
diagnost
kit
time
perform
cost
antigen
detect
current
method
choic
small
middl
size
laboratori
sweden
immunofluoresc
assay
use
feasibl
long
number
sampl
remain
per
day
elisa
assay
practic
nasopharyng
aspir
use
hospit
patient
swab
commonli
use
physician
offic
antigen
detect
allow
result
day
increas
interest
clinician
send
specimen
laboratori
local
laboratori
abl
store
send
sampl
central
refer
laboratori
epidemiolog
purpos
influenza
infect
better
preserv
freez
temperatur
specimen
frozen
unless
longterm
storag
requir
central
laboratori
antigen
detect
elisa
immunofluoresc
still
good
method
genom
amplif
howev
method
choic
set
viru
isol
also
perform
epidemiolog
purpos
refer
laboratori
cultur
subtyp
sequenc
virus
well
determin
antivir
sensit
duti
central
refer
laboratori
share
inform
obtain
other
evalu
methodolog
done
set
use
care
plan
sampl
storag
transport
laboratori
import
sampl
evalu
assay
order
obtain
full
view
valu
reid
et
al
tendenc
today
use
combin
test
design
true
posit
magnard
et
al
singl
test
consid
gold
standard
method
must
standard
sinc
reproduc
differ
set
import
continu
intern
qualiti
assess
test
perform
diagnost
level
also
necess
recent
compar
studi
sensit
differ
method
detect
influenza
viru
infect
evalu
specimen
posit
one
method
pcr
assay
ha
gene
target
elisa
cell
cultur
magnard
et
al
sensit
vari
method
posit
result
obtain
pcr
use
ha
gene
target
sensit
wherea
posit
elisa
cell
cultur
conclus
could
drawn
specif
serolog
usual
help
earli
diagnosi
respiratori
viru
infect
sensit
around
use
retrospect
patient
understand
epidemiolog
studi
gener
elisa
assay
perform
better
hemagglutinationinhibit
assay
better
complement
fixat
assay
revers
transcriptas
pcr
provid
rel
fast
result
day
sensit
sensit
increas
use
nest
approach
howev
test
suscept
contamin
routin
laboratori
set
technic
demand
difficulti
implement
due
lack
standard
taqman
glaxo
wellcom
quantit
pcr
similar
ordinari
pcr
specif
forward
revers
primer
use
addit
probe
includ
label
fluoresc
report
quencher
dye
pcr
progress
exonucleas
activ
taq
polymeras
cleav
probe
releas
fluoresc
report
detect
laser
base
instrument
import
featur
assay
real
time
fluoresc
measur
everi
graphic
measur
creat
time
run
thu
taqman
pcr
offer
rapid
result
usual
h
sensit
less
prone
contamin
post
pcr
sampl
handl
done
standard
protocol
taqman
techniqu
use
detect
influenza
virus
ha
gene
segment
sought
stock
viru
assay
detect
far
gene
copi
differ
vaccin
clinic
strain
influenza
test
detect
amplif
effici
one
patient
follow
serial
sampl
decreas
intens
viru
detect
observ
time
pilot
studi
taqman
pcr
use
determin
viral
load
differ
respiratori
virus
nasal
swab
sampl
obtain
patient
cystic
fibrosi
cf
virus
test
rhinoviru
ncr
influenza
proteina
b
rsv
polymeras
adenoviru
hexon
piv
hn
coronaviru
nasal
swab
obtain
children
attend
cf
clinic
test
blind
investig
use
taqman
pcr
rsv
primerprob
first
design
region
amplifi
contain
amplicon
interest
test
abl
detect
littl
one
copi
order
test
variabl
test
swab
sampl
triplic
swab
seed
rsv
extract
test
taqman
assay
result
consist
variabl
around
low
concentr
one
freezethaw
virtual
rsv
lost
influenza
viru
seem
less
affect
taqman
method
use
determin
whether
respiratori
virus
caus
exacerb
cf
patient
determin
whether
threshold
titer
occur
whether
window
opportun
therapeut
intervent
threshold
titer
clinic
exacerb
appear
gene
copi
virus
detect
influenza
adenoviru
rsv
rhinovirus
studi
suggest
feasibl
determin
viral
load
respiratori
secret
cf
patient
use
nasal
swab
might
possibl
correl
viral
load
clinic
symptom
determin
threshold
titer
exacerb
rhinoviru
rv
enter
nose
direct
contact
inhal
infecti
droplet
rapidli
within
min
transport
lymphoid
area
nasopharynx
intracellular
adhes
receptor
rhinovirus
present
abund
domelik
cell
epitheli
layer
studi
done
person
challeng
rv
nose
shown
infect
gwaltney
rv
low
howev
infect
becam
ill
import
risk
factor
occurr
rv
infect
absenc
specif
antibodi
replic
cycl
rv
nose
similar
cell
cultur
system
take
approxim
h
symptom
scratchi
throat
appear
challeng
individu
near
time
complet
viru
produc
h
sign
symptom
common
cold
includ
rhinorrea
sneez
sore
throat
cough
rv
caus
signific
rhiniti
diseas
also
involv
sinus
caus
rhinosinus
infrequ
abnorm
eustachian
tube
function
middl
ear
pressur
gwaltney
ruckert
viral
sinus
selflimit
ill
character
thick
secret
sinus
seen
comput
tomographi
ct
adult
maxillari
sinu
adult
contain
averag
volum
ml
drainag
occur
mm
diamet
infundibulum
sinu
caviti
contain
seromuc
gland
mani
goblet
cell
rv
infect
may
stimul
mucou
product
goblet
cell
also
nose
blow
gener
mmhg
pressur
sneez
cough
gener
mmhg
pressur
nose
blow
radiograph
dye
place
nose
forc
sinus
symptom
product
directli
attribut
viral
replic
multipl
pathway
inflamm
exist
nasal
tissu
specif
symptom
relat
part
pathway
histamin
stimul
sneez
rhinorrea
nasal
obstruct
sore
throat
first
gener
second
gener
antihistamin
block
sneez
reduc
nasal
secret
volum
patient
cold
kinin
caus
vasodil
increas
vascular
permeabl
result
increas
nasal
secret
transud
plasma
stimul
pain
nerv
end
sore
throat
stimul
releas
histamin
mast
cell
increas
level
kinin
observ
nasal
secret
natur
experiment
rhinoviru
cold
prostaglandin
increas
vascular
permeabl
induc
bronchoconstrict
given
nose
result
rhinorrea
nasal
obstruct
cough
increas
level
found
secret
patient
rv
cold
parasympathet
nervou
system
induc
sneez
reflex
secret
mucou
gland
import
begin
treatment
first
indic
cold
burden
symptom
occur
within
first
day
ill
nose
blow
lead
deposit
nasal
secret
within
nasal
sinus
earli
treatment
may
use
first
gener
antihistamin
reduc
volum
nasal
secret
frequenc
sneez
nonsteroid
antiinflammatori
agent
reduc
cough
headach
myalgia
approach
prevent
rhinoviru
infect
limit
vaccin
feasibl
serotyp
block
transmiss
difficult
young
children
block
viral
attach
cellular
receptor
partial
success
difficulti
maintain
effect
concentr
solubl
nose
stop
viral
replic
drug
nucleic
acid
antagonist
capsid
bind
drug
proteas
inhibitor
present
problem
difficulti
maintain
adequ
nasal
concentr
drug
side
effect
develop
resist
also
antivir
treatment
alon
effect
reduc
ill
appear
necessari
also
block
inflammatori
pathway
activ
infect
achiev
maximum
symptom
reduct
evid
combin
therapi
antivir
antiinflammatori
drug
lead
superior
clinic
efficaci
recent
studi
use
rv
challeng
model
dose
begin
h
viru
challeng
effect
administr
combin
interferon
intranas
drop
clorpheniramin
oral
ibuprofen
compar
placebo
nasal
drop
two
drug
placebo
drop
capsul
sizabl
effect
reduc
total
symptom
score
note
full
treatment
group
compar
placebo
trend
superior
benefit
full
versu
partial
treatment
also
note
suggest
interferon
provid
independ
benefit
summari
rv
reach
nasal
passag
transport
adenoid
mucocilliari
action
attach
receptor
epitheli
cell
appear
first
replic
adenoid
area
nasopharynx
viru
cytopatholog
activ
inflammatori
mediat
neurogen
pathway
produc
vascular
transud
pain
nerv
activ
activ
sneez
cough
symptom
begin
upper
airway
earli
h
infect
abnorm
appear
osteomeat
complex
sinu
caviti
eustachian
tube
middl
ear
individu
rv
cold
symptom
begin
declin
third
day
infect
median
durat
one
week
viral
excret
may
continu
long
week
well
diseas
subsid
high
suscept
nose
infect
rapid
onset
replic
earli
peak
viral
shed
rel
brief
opportun
antivir
treatment
effect
role
inflammatori
mediat
ill
product
support
idea
earli
treatment
attack
viru
mediat
achiev
optim
treatment
effect
adenovirus
common
human
pathogen
caus
broad
spectrum
diseas
includ
conjunct
keratoconjunct
pneumonia
heart
diseas
hepat
nephriti
gastroenter
ubiquit
virus
typic
exhibit
latenc
persist
shed
diagnosi
enhanc
pcr
allow
specif
type
primer
avail
adenovirus
serotyp
adenoviru
divid
six
subgenera
af
exhibit
distinctli
differ
organ
tropism
addit
recent
molecular
epidemiolog
divid
mani
serotyp
genotyp
design
b
c
etc
differ
patient
popul
tend
acquir
diseas
specif
adenoviru
subgenra
adenoviru
subgenera
b
c
import
caus
pneumonia
patient
primari
immunodefici
b
adenovirus
predominantli
found
renal
transplant
recipi
c
virus
liver
transplant
recipi
diseas
caus
certain
adenoviru
serotyp
particularli
type
sever
often
lethal
popul
serotyp
caus
sever
even
fatal
diseas
immunocompet
children
adult
healthi
adult
sever
lobar
pneumonia
associ
adenoviru
young
children
adenoviru
pneumonia
develop
bronchiectasi
hyperluc
lung
associ
lung
fibrosi
fatal
case
occur
children
year
age
america
epidem
keratoconjunct
caus
adenoviru
adenoviru
isol
survey
trachoma
associ
diseas
sinc
outbreak
genit
eye
diseas
caus
adenoviru
differ
serotyp
caus
keratoconjunct
one
caus
genit
eye
diseas
found
singl
amino
acid
chang
previous
unrecogn
diseas
entiti
associ
adenoviru
children
diagnos
myocard
found
adenoviru
biopsi
materi
pcr
schowengerdt
et
al
similarli
adult
patient
left
ventricular
myocardi
dysfunct
myocard
adenoviru
dna
found
paushing
et
al
adenoviru
type
outbreak
occur
april
june
children
die
previous
unrecogn
entiti
character
cardiopulmonari
failur
arrythmia
new
viru
call
sibu
viru
identifi
cerebrospin
fluid
brain
heart
children
cardosa
et
al
viru
also
associ
acut
non
fatal
flacid
paralysi
four
children
emerg
viru
fastidi
show
tropism
central
nervou
system
associ
cardiac
arrest
appear
relat
subgenu
b
virus
recent
data
provid
understand
vari
adenoviru
tropism
virion
fiber
differ
length
serv
ligand
capsid
host
cell
receptor
variat
length
necessari
viru
overcom
differ
charg
viral
capsid
cell
surfac
usual
acid
sequenc
fiber
gene
member
subgenera
reveal
isoelectr
point
outer
part
fiber
knob
rang
within
fiber
knob
two
domain
identifi
first
domain
contain
mutat
lose
hemagglutin
capac
adenovirus
predilect
eye
display
high
posit
charg
fiber
knob
adenovirus
alkalin
region
isoelectr
point
correspond
second
domain
delimit
two
amino
acid
residu
uniqu
adenovirus
caus
epidem
keratoconjunct
adenovirus
subgenera
c
e
f
exhibit
affin
coxsacki
adenoviru
host
cell
receptor
car
pentamer
integrin
caus
epidem
keratoconjunct
bind
sialic
acid
host
cell
glycoprotein
pathogen
adenovirus
partli
explain
fact
gener
induc
interferon
product
resist
interferon
action
accord
caus
lethal
diseas
sensit
interferon
viru
sensit
interferon
associ
presenc
virusassoci
rna
varna
genom
import
splice
rna
transcrib
viru
rna
polymeras
two
varna
genom
found
viru
resist
interferon
import
differ
adenoviru
serotyp
vari
geograph
molecular
epidemiolog
respiratori
adenovirus
studi
sinc
mutual
exclud
switch
took
place
europ
australia
beij
predomin
succeed
adenoviru
predomin
pathogen
beij
us
predomin
europ
australia
militari
recruit
us
receiv
adenoviru
vaccin
includ
sinc
vaccin
discontinu
reemerg
case
outbreak
occur
south
america
caus
unusu
sever
pneumonia
death
emerg
viru
determin
adenoviru
recombin
contain
fiber
appear
japan
infect
formerli
rare
acut
otiti
media
aom
common
caus
physician
offic
visit
children
year
age
lead
caus
antibiot
prescript
us
peak
age
aom
month
highest
incid
occur
winter
viru
season
although
diseas
gener
consid
bacteri
diseas
treat
antibiot
clear
respiratori
virus
play
signific
role
pathogenesi
clinic
cours
outcom
aom
ten
children
viral
urti
develop
aom
concurr
shortli
urti
otiti
media
develop
within
day
case
within
day
within
first
week
virus
detect
respiratori
secret
middl
ear
fluid
proport
children
aom
respect
depend
diagnost
method
chonmaitre
heikkinen
caus
aom
bacteri
alon
case
pneumonia
h
influenza
moraxella
catarrhali
predomin
pathogen
case
viru
alon
found
case
combin
viru
bacteria
detect
data
compil
utmb
studi
current
diagnost
method
pathogen
found
case
respiratori
virus
associ
aom
includ
rsv
parainfluenza
virus
influenza
virus
rhinoviru
enteroviru
adenoviru
coronaviru
cytomegaloviru
herp
simplex
viru
studi
heikkinen
et
al
rsv
shown
ototrop
viru
middl
ear
invas
children
aom
infect
rsv
rate
parainfluenza
influenza
enteroviru
adenoviru
also
influenza
vaccin
children
result
signific
reduct
aom
influenza
season
belsh
et
al
data
vitro
studi
experiment
anim
adult
volunt
children
uri
aom
suggest
virus
may
involv
pathogenesi
aom
sever
way
infect
upper
respiratori
tract
induc
product
variou
cytokin
inflammatori
mediat
histamin
kinin
interleukin
arachidon
acid
metabolit
tnfalpha
possibl
mediat
mani
substanc
shown
induc
inflammatori
process
lead
mucocilliari
damag
dysfunct
impair
middl
ear
ventil
experiment
influenza
infect
anim
result
middl
ear
pressur
chang
tympan
membran
inflamm
damag
disappear
ciliat
epitheli
cell
increas
eustachian
tube
mucou
cellular
debri
preschool
children
uri
signific
neg
middl
ear
pressur
occur
second
day
ill
eustachian
tube
dysfunct
also
occur
adult
rhinoviru
influenza
experiment
infect
virus
may
also
alter
neutrophil
function
enhanc
nasopharyng
bacteri
colon
adher
event
along
eustachian
tube
dysfunct
lead
invas
middl
ear
bacteria
viru
microbi
agent
reach
middl
ear
anoth
inflammatori
cascad
initi
lead
middl
ear
fluid
accumul
symptom
aom
evid
date
also
suggest
activ
viral
infect
middl
ear
respiratori
tract
time
aom
diagnosi
associ
poor
respons
antibiot
effect
use
viral
vaccin
prevent
respiratori
viral
infect
effect
treatment
antivir
drug
like
lead
reduct
incid
improv
outcom
common
diseas
f
g
surfac
glycoprotein
rsv
involv
host
immun
respons
particularli
antibodi
respons
viral
protein
involv
cell
respons
young
children
month
age
often
sever
rsv
bronchiol
repeat
infect
may
occur
factor
contribut
sever
diseas
younger
age
includ
immatur
immun
system
presenc
matern
antibodi
transfer
placenta
collostrum
may
interfer
immun
respons
declin
natur
howev
passiv
administr
antibodi
shown
confer
protect
rsv
young
infant
controversi
area
pathogenesi
rsv
role
cell
induc
immun
base
observ
formalin
inactiv
vaccin
use
infant
experi
anim
model
specul
enhanc
pulmonari
histopatholog
relat
higher
tcell
respons
infect
accompani
shift
respons
toward
respons
cell
involv
recoveri
pathogenesi
rsv
diseas
balanc
protect
diseaseenhanc
effect
cell
import
consid
develop
intervent
strategi
also
observ
correl
sever
diseas
increas
ige
histamin
product
especi
children
asthma
eosinophil
recruit
degranul
lung
parenchyma
may
contribut
lung
patholog
develop
prevent
strategi
import
induc
mucos
system
antibodi
understand
mechan
pathogenesi
rsv
diseas
identif
tcell
epitop
rsv
role
immunopathogenesi
vaccin
target
import
cell
two
infant
b
month
age
sever
rsv
diseas
clone
limit
dilut
screen
rsv
specif
prolif
respons
clone
obtain
way
mostli
clone
produc
mainli
interferon
gamma
phenotyp
marker
one
children
specif
f
protein
protein
found
major
specif
rsv
clone
reactiv
f
protein
protein
littl
reactiv
g
protein
found
clone
specif
f
protein
react
one
two
peptid
mhc
restrict
recognit
test
use
panel
b
cell
line
cell
react
thu
experi
describ
identif
two
epitop
f
protein
specif
genotyp
restrict
understand
pathogenesi
rsv
young
children
cohort
infant
acut
respiratori
infect
within
first
month
life
follow
sever
mild
infect
separ
comparison
group
cytokin
measur
week
infect
reveal
differ
increas
product
proinflammatori
cytokin
plasma
sever
diseas
inflammatori
cell
nasopharyng
wash
infect
analyz
lymphocyt
polymorphonuclear
cell
ige
eosinophil
mast
cell
littl
differ
observ
children
mild
versu
sever
rsv
diseas
indic
respons
rsv
specif
cell
respons
sought
acut
admiss
convalesc
week
phase
infect
children
acut
phase
indic
select
product
sever
group
compar
mild
group
convalesc
phase
differ
two
group
induct
variou
cytokin
intracellular
stain
perform
interferon
gamma
cell
clear
differ
observ
sever
mild
group
conclus
infant
sever
rsv
infect
exhibit
higher
level
plasma
pronounc
rsv
specif
type
like
respons
observ
eosinophil
found
np
wash
specimen
predomin
cytokin
produc
interferon
gamma
minim
amount
note
data
support
hypothesi
sever
rsv
infect
result
lymphocyt
respons
cell
mediat
immun
cmi
thought
play
role
clear
viral
infect
normal
children
may
shed
rsv
day
cmi
defici
children
shed
viru
month
moreov
adopt
transfer
tcell
clear
virus
immunodefici
anim
number
studi
anim
adult
children
show
primari
infect
rsv
induc
respons
predominantli
cytotox
lymphocyt
ctl
respons
respons
studi
normal
children
month
age
rsv
infect
ctl
respons
correl
diseas
sever
anoth
studi
ctl
respons
detect
infant
hospit
bronchiol
ctl
mild
diseas
evalu
compar
rsv
specif
ctl
respons
cytokin
product
infant
children
identifi
role
immun
diseas
rsv
infant
enrol
birth
follow
three
consecut
year
blood
obtain
rsv
season
well
acut
respiratori
infect
requir
medic
attent
year
one
studi
infant
infect
detect
viru
isol
six
antibodi
rise
year
one
child
infect
standard
ctl
assay
use
averag
ctl
activ
infant
low
enrol
progress
increas
first
season
increas
ctl
activ
relat
exposur
rsv
low
level
interferon
gamma
assay
supernat
note
enrol
level
also
increas
time
quit
high
initi
season
progress
averag
level
decreas
direct
correl
observ
ctl
activ
interferon
gamma
level
invers
correl
observ
infant
viru
isol
among
medic
attend
lower
respiratori
diseas
tend
develop
ctl
activ
develop
ctl
activ
year
reduc
likelihood
medic
attend
ill
year
even
infect
signific
advanc
use
live
attenu
cold
adapt
influenza
vaccin
includ
follow
vaccin
updat
annual
match
fda
recommend
trival
inactiv
vaccin
produc
consist
titer
tcid
per
strain
nasal
spray
devic
produc
larg
particl
aerosol
use
deliv
viru
children
adult
take
approxim
pfu
strain
infect
seroneg
children
viru
shed
respiratori
secret
titer
ml
day
seroneg
children
revers
wild
type
detect
monoval
bival
trival
vaccin
well
toler
dose
pfu
per
strain
per
dose
interfer
seen
strain
overcom
administr
second
dose
month
later
broad
antibodi
respons
observ
includ
serum
secretori
iga
antibodi
clinic
trial
coldadapt
attenu
influenza
vaccin
children
adult
indic
suitabl
gener
use
prevent
influenza
two
year
multicent
doubleblind
placebocontrol
efficaci
trial
vaccin
nasal
spray
children
month
age
overal
vaccin
efficaci
prevent
cultur
confirm
influenza
awuhan
influenza
b
belsh
et
al
second
year
studi
vaccin
effect
prevent
influenza
asydney
viru
drift
variant
natur
awuhan
infect
year
placebo
recipi
led
efficaci
asydney
year
live
vaccin
therefor
appear
effect
natur
infect
instanc
children
year
age
part
seroneg
significantli
higher
respons
vaccin
older
children
howev
differ
protect
efficaci
vaccin
among
differ
age
group
vaccin
also
highli
protect
influenza
associ
otiti
media
furthermor
influenza
ill
vaccin
children
milder
placebo
recipi
lower
respiratori
diseas
occur
placebo
recipi
year
seriou
advers
event
associ
vaccin
trial
day
first
dose
signific
increas
rhinorrea
small
increas
incid
low
grade
fever
vaccin
recipi
observ
dose
revaccin
year
later
otiti
media
increas
day
post
vaccin
compar
vaccin
placebo
group
higher
background
rate
among
subject
came
household
two
sibl
seroconvers
vaccin
viru
observ
vaccin
particip
suggest
vaccin
viru
transmit
although
endpoint
pediatr
trial
determin
effect
vaccin
follow
observ
made
reduct
febril
ill
year
year
among
vaccine
reduct
case
otiti
media
year
respect
febril
otiti
media
reduc
year
year
signific
reduct
observ
antibiot
use
day
miss
daycar
children
work
lost
parent
sinc
influenza
caus
diseas
year
studi
conduct
determin
efficaci
experiment
challeng
attenu
vaccin
strain
intranas
spray
perform
vaccin
viru
challeng
associ
seriou
advers
event
vaccin
efficaci
ci
prevent
shed
viru
challeng
serum
hai
antibodi
nasal
wash
iga
antibodi
prechalleng
specimen
correl
signific
protect
infect
studi
duplic
pattern
protect
observ
natur
influenza
outbreak
influenza
influenza
b
children
furthermor
indic
children
protect
viral
shed
measur
immun
either
mucos
iga
serum
hai
neutral
antibodi
effect
trial
work
adult
demonstr
influenzalik
ill
significantli
reduc
intranas
live
attenu
vaccin
influenza
season
nichol
et
al
vaccin
reduc
lost
work
day
reduc
antibiot
overthecount
medic
use
clinic
trial
elderli
subject
copd
hivi
infect
adult
patient
asthma
reveal
vaccin
safe
use
live
attenu
vaccin
elderli
combin
vaccin
inactiv
vaccin
current
evalu
thu
intranas
live
attenu
vaccin
signific
new
tool
prevent
influenza
complic
gener
use
vaccin
healthi
children
adult
age
support
clinic
trial
data
use
special
popul
elderli
studi
compar
studi
live
attenu
vaccin
versu
inactiv
vaccin
necessari
howev
current
trial
indic
live
attenu
influenza
viru
vaccin
might
result
broader
immun
respons
among
young
children
belsh
et
al
b
mortal
associ
lower
respiratori
tract
diseas
shown
substanti
steadi
increas
sinc
excess
mortal
influenza
also
appear
increas
simonsen
et
al
annual
averag
number
death
influenza
increas
accompani
increas
mortal
increas
rate
hospit
pneumonia
peopl
year
strategi
prevent
lrti
need
purpos
studi
perform
templ
tx
determin
indirect
effect
univers
vaccin
young
children
influenza
epidem
commun
specif
immun
preschool
school
age
children
live
attenu
influenza
vaccin
significantli
reduc
medic
attend
ill
commun
contact
regardless
immun
statu
vaccin
easi
administ
well
toler
children
potenti
use
purpos
commun
studi
commun
larg
clinic
central
texa
data
comparison
obtain
clinic
hmo
three
central
texa
citi
data
avail
estim
vaccin
efficaci
studi
popul
children
vaccin
approxim
year
age
year
age
seriou
advers
event
seriou
ill
sometim
associ
influenza
occur
week
immedi
vaccin
medic
attend
acut
respiratori
ill
maari
rate
increas
follow
vaccin
compar
prevaccin
day
postvaccin
viru
cultur
person
seek
medic
care
acut
respiratori
ill
use
defin
begin
end
influenza
season
influenza
b
isol
person
cultur
posit
influenza
studi
comparison
commun
cocircul
rsv
occur
epidem
total
children
vaccin
direct
effect
vaccin
demonstr
intens
period
influenza
season
combin
age
group
signific
reduct
maari
observ
year
age
group
reduct
compar
age
match
elig
non
vaccine
commun
year
age
group
reduct
note
year
age
group
reduct
maari
influenza
viru
surfac
glycoprotein
antigen
neuraminidas
na
role
immun
recogn
year
yet
remain
unmonitor
compon
inactiv
vaccin
potenti
engend
infectionpermiss
immun
administ
singl
vaccin
compon
exploit
studi
report
concern
effort
improv
present
vaccin
supplement
predomin
hemagglutinin
ha
antigen
recombin
na
rna
couch
et
al
johansson
et
al
johansson
et
al
base
extens
anim
studi
previou
clinic
trial
hana
antigen
hybrid
anticip
addit
purifi
na
insur
na
vaccin
present
adequ
amount
balanc
ratio
ha
na
reduc
antigen
competit
predomin
antiha
respons
suppress
antina
respons
provid
adequ
amount
antigen
less
subject
antigen
drift
na
thu
provid
backup
immun
vaccin
ha
match
well
new
viru
mice
rna
elicit
protect
na
antibodi
effect
homolog
challeng
viru
reduct
lung
viru
also
reduc
lung
viru
titer
almost
follow
heterovari
viru
challeng
measur
dose
respons
baculoviru
recombin
rna
johannesburg
human
cincinnati
verifi
safeti
immunogen
dose
rang
mg
carri
phase
clinic
trial
similar
cincinnati
popul
trial
group
subject
receiv
either
tiv
commerci
subvirion
trival
vaccin
tivrna
placebo
mous
model
rna
deriv
viru
present
tiv
vaccin
subject
challeng
viru
succeed
heterovari
viru
shown
ha
na
antigen
relat
vaccin
viru
summari
demonstr
comparison
tiv
alon
rna
tiv
result
increas
na
antibodi
titer
associ
less
viral
shed
reduct
symptomatolog
face
nonhomolog
challeng
rna
first
recombin
na
use
human
safe
immunogen
alon
combin
tiv
difficulti
confound
evalu
includ
closer
anticip
antigen
relationship
ha
immun
result
reduct
infect
rna
tiv
tiv
group
ananchang
viru
challeng
attenu
extent
mild
uri
symptom
occur
placebo
group
inadequ
number
volunt
show
statist
signific
although
data
viral
shed
show
uniform
trend
favor
supplement
vaccin
background
studi
well
data
present
indic
import
correct
probabl
na
defici
present
vaccin
adequ
level
na
antibodi
may
reduc
viral
shed
therefor
chanc
diseas
transmiss
shown
balanc
respons
ha
slowli
evolv
na
antigen
offer
back
ha
drift
part
prepar
futur
influenza
pandem
need
evalu
conventionallyprepar
novel
influenza
vaccin
immunolog
popul
phase
studi
healthi
adult
aducksingaporeq
given
mg
ha
day
observ
blind
random
parallel
dose
rang
studi
seriou
advers
event
although
greater
incid
local
pain
recipi
oilinwat
adjuv
adjuv
vaccin
ott
et
al
serum
hi
antibodi
titer
develop
subject
day
first
dose
subject
day
second
dose
convent
adjuv
vaccin
respect
trend
toward
increas
respons
increas
dose
note
convent
vaccin
opposit
true
adjuv
vaccin
increas
neutral
antibodi
titer
develop
subject
day
first
dose
subject
day
second
dose
convent
adjuv
vaccin
respect
trend
increas
respons
receipt
second
dose
adjuv
vaccin
geometr
mean
titer
gmt
hi
neutral
antibodi
day
significantli
differ
prevaccin
level
convent
vaccin
recipi
significantli
greater
adjuv
vaccin
respons
elicit
convent
vaccin
suggest
reli
upon
evok
protect
antibodi
level
human
emerg
pandem
influenza
viru
vaccin
clearli
boost
hi
neutral
antibodi
respons
immunolog
subject
least
two
dose
vaccin
appear
requir
elicit
adequ
respons
lymphocyt
approach
influenza
next
pandem
cell
see
process
viral
peptid
surfac
infect
cell
present
conjunct
histocompat
molecul
anim
studi
demonstr
passiv
transfer
posit
cell
clone
possess
specif
lymphocyt
cytotox
capabl
influenza
viru
reduc
pulmonari
viru
load
protect
mice
death
howev
studi
mice
rais
concern
util
approach
gener
cell
repertoir
mice
limit
present
limit
data
human
hand
epitop
influenza
identifi
nonsystemat
studi
human
lymphocyt
recent
seri
experi
human
lymphocyt
stimul
viru
bulk
cultur
cytotox
test
kill
virus
high
degre
use
recombin
vaccinia
target
heterogen
ctl
respons
note
np
highest
half
dozen
protein
recogn
line
stimul
cultur
clone
histocompat
protein
involv
recognit
one
donor
determin
hla
abl
present
multipl
epitop
np
well
epitop
ctl
smaller
number
clone
detect
mostli
react
epitop
ha
na
emerg
avian
influenza
viru
hong
kong
clone
human
lymphocyt
test
non
human
viru
speci
clone
test
abl
kill
swine
anew
jersey
viru
express
target
hong
kong
strain
well
control
viru
therefor
human
ctl
respons
influenza
viru
larg
cross
reactiv
mani
cross
reactiv
ctl
recogn
conserv
epitop
avian
swine
influenza
virus
well
human
virus
ctl
respons
subject
receiv
standard
inactiv
influenza
vaccin
vaccin
formul
immunostimul
complex
iscom
quantit
influenza
vaccin
formul
iscom
carrier
shown
taken
human
cell
stimul
influenza
viru
specif
cell
vitro
doubl
blind
clinic
trial
demonstr
one
dose
iscom
vaccin
significantli
increas
level
influenza
viru
specif
cross
reactiv
cell
memori
recipi
compar
standard
vaccin
group
level
increas
ctl
memori
cell
respons
correl
increas
level
ifn
gamma
produc
cell
propos
augment
ctl
memori
cell
goal
design
influenza
vaccin
emerg
influenza
virus
revers
genet
influenza
viru
initi
sever
year
ago
ribonucleoprotein
complex
rnp
reconstitut
vitro
rna
transcrib
plasmid
dna
presenc
polymeras
pol
protein
nucleoprotein
isol
purifi
influenza
viru
vitroreconstitut
rnp
transfect
cell
also
infect
helper
influenza
viru
helper
viru
provid
remain
viral
protein
rna
segment
result
gener
transfect
virus
helper
virusbas
rescu
system
use
rna
pol
promoterdriven
revers
genet
techniqu
subsequ
establish
segment
encod
neuraminidas
na
hemagglutinin
ha
nuclear
export
protein
protein
nucleoprotein
np
polymeras
basic
protein
result
led
develop
entir
plasmid
driven
system
mixtur
eight
plasmid
express
individu
rna
segment
influenza
viru
truncat
human
pol
promot
use
recov
infecti
viru
clone
cdna
addit
previous
use
rna
complex
plasmid
replac
plasmid
express
protein
control
adenoviru
major
late
promot
use
system
infecti
particl
obtain
h
vero
cell
cultur
fodor
et
al
ns
gene
code
protein
splice
messeng
rna
protein
mani
differ
function
describ
protein
perhap
import
activ
host
cell
interferon
antagon
influenza
b
viru
express
alter
protein
result
alter
interferon
respons
mutant
repres
potenti
novel
vaccin
garciasastr
et
al
talon
et
al
viru
use
infect
cell
cell
produc
interferon
activ
counter
strong
antiinterferon
respons
viru
viru
abl
product
infect
cell
genet
alter
viru
encod
full
length
amino
termin
amino
acid
anoth
genet
deriv
viru
delta
lack
open
read
frame
delta
viru
infect
cell
stimul
produc
interferon
viru
induc
antiinterferon
activ
replic
restrict
host
viru
intermedi
effect
attenu
vitro
embryon
egg
differ
age
differ
capabl
induc
interferon
three
virus
inocul
differ
age
embryon
egg
titer
pfu
obtain
egg
delta
grew
egg
log
reduct
observ
egg
growth
egg
viru
show
intermedi
growth
delta
virus
mice
infect
virus
pfu
delta
kill
normal
mice
viru
mice
immun
singl
dose
pfu
delta
complet
protect
observ
lower
dose
protect
viru
either
dose
protect
immun
mice
challeng
week
later
either
influenza
b
viru
system
ns
gene
also
code
protein
nuclear
export
protein
two
virus
contain
truncat
protein
amino
acid
respect
deriv
byamagata
viru
influenza
viru
shorter
would
grow
older
embryon
egg
wild
type
viru
grew
high
titer
egg
grew
egg
dayold
egg
sinc
byamagata
wildtyp
result
lethal
infect
mice
lung
titer
measur
challeng
titer
pfug
observ
lung
wild
viru
challeng
two
attenu
strain
bare
detect
level
week
mice
infect
either
complet
protect
wild
type
challeng
summari
influenza
viru
infect
cell
induc
interferon
respons
cell
win
unless
viru
strong
antiinterferon
activ
mediat
attenu
strain
virus
produc
prepar
intermedi
attenu
strain
neither
temperatur
sensit
cold
adapt
principl
modul
antiinterferon
respons
viru
vaccin
develop
may
work
influenza
viru
also
virus
molecular
biolog
techniqu
revers
genet
util
develop
live
attenu
viru
vaccin
subgroup
b
strain
rsv
parainfluenza
virus
type
prevent
seriou
lower
respiratori
tract
diseas
caus
virus
genet
basi
attenu
defin
variou
rsv
piv
vaccin
candid
inform
use
gener
larg
menu
attenu
mutat
rsv
piv
specif
mutat
delet
anim
gene
substitut
offer
possibl
heighten
stabil
attenu
phenotyp
follow
replic
vivo
possibl
combin
mutat
menu
deriv
novel
attenu
virus
exhibit
proper
balanc
replic
attenu
immunogen
need
success
live
attenu
vaccin
also
possibl
rapidli
produc
new
vaccin
candid
antigen
chimer
protect
antigen
one
viru
substitut
serotyp
differ
vaccin
candid
previous
shown
exhibit
right
level
attenu
attenu
rsv
piv
virus
use
vector
protect
antigen
human
viral
pathogen
rsv
piv
strain
current
evalu
children
phase
blind
random
trial
gener
rsv
vaccin
given
nose
drop
one
dose
pfu
two
dose
month
interv
given
younger
children
karron
et
al
infect
rsv
cold
adaptedtemperatur
sensit
attenu
vaccin
cpt
result
febril
lower
respiratori
tract
diseas
seroposit
seroneg
children
month
age
children
month
age
younger
children
nasal
congest
occur
day
vaccin
administr
last
h
accompani
difficulti
sleep
feed
along
fact
viru
replic
fairli
high
titer
indic
need
attenu
viru
relationship
amount
pattern
viru
shed
upper
respiratori
tract
level
matern
acquir
antibodi
age
child
youngest
children
minim
viru
shed
note
second
dose
vaccin
among
shed
viru
first
dose
protect
confer
howev
appar
relat
develop
detect
serum
igg
antibodi
respons
children
month
age
serum
igg
antibodi
respons
f
andor
g
protein
elisa
howev
children
month
age
demonstr
respons
two
dose
virtual
none
singl
dose
howev
infant
develop
serum
iga
antibodi
develop
nasal
wash
iga
antibodi
antibodi
mostli
direct
g
protein
viral
shed
note
second
dose
vaccin
among
serum
iga
antibodi
respons
thu
potenti
correl
immun
identifi
month
old
children
protect
rsv
associ
urti
otiti
media
observ
vaccin
children
subsequ
season
live
attenu
piv
vaccin
also
evalu
aim
induct
serum
mucos
antibodi
karron
et
al
b
vaccin
passag
time
cold
adapt
temperatur
sensit
attenu
varieti
anim
model
second
vaccin
candid
deriv
wild
type
bovin
viru
similarli
attenu
human
dose
either
piv
vaccin
administ
nasal
drop
older
children
younger
seroneg
children
dose
rang
test
neither
vaccin
induc
respiratori
ill
virus
poorli
infecti
seroposit
children
month
old
group
antibodi
rise
vaccin
bovin
vaccin
surfac
antigen
share
homolog
human
therefor
older
seroposit
children
adult
vaccin
like
bovin
strain
safe
immunogen
given
seroneg
children
high
level
infect
seen
judg
antibodi
respons
viru
shed
viru
shed
shown
maintain
ts
coldadapt
phenotyp
lower
dose
vaccin
reduc
infect
rate
amount
shed
trial
start
human
piv
vaccin
children
given
two
dose
regimen
month
interv
given
month
apart
vaccin
attenu
genet
stabl
retain
ca
phenotyp
first
dose
vaccin
children
shed
viru
period
day
mean
peak
titer
around
tcid
nasal
wash
children
shed
viru
second
dose
vaccin
shed
period
shorter
mean
peak
titer
lower
serum
hai
respons
occur
either
dose
rsv
serum
iga
respons
seen
overal
parainfluenza
vaccin
safe
healthi
children
young
month
age
replic
effici
young
children
genet
stabl
induc
serum
iga
detect
neutral
igg
antibodi
respons
major
compon
inhibit
serum
antibodi
product
vaccin
young
infant
seem
level
matern
antibodi
rsv
singl
dose
protect
vaccin
challeng
altern
live
attenu
rsv
vaccin
novel
recombin
rsv
subunit
vaccin
use
fragment
g
protein
design
investig
vaccin
compos
fragment
streptococc
protein
g
albumin
bind
domain
fuse
genet
highli
conserv
amino
acid
fragment
rsv
g
protein
vaccin
highli
purifi
well
character
immunogen
protect
rodent
nonhuman
primat
well
efficaci
neonat
murin
model
presenc
high
level
matern
deriv
antibodi
power
et
al
siegrist
et
al
evid
enhanc
patholog
challeng
anim
given
vaccin
object
studi
determin
safeti
immunogen
healthi
seroposit
young
adult
subject
receiv
mg
aluminum
phosphat
n
salin
placebo
n
twice
three
time
monthli
interv
local
reaction
consist
mild
pain
inject
site
vaccin
recipi
compar
placebo
recipi
system
reaction
seriou
advers
event
vaccin
antibodi
respons
elisa
neutral
assay
higher
mg
group
inject
twofold
rise
rsva
elisa
antibodi
evid
subject
mg
group
fourfold
rise
antibodi
seen
subject
respect
subject
demonstr
twofold
increas
level
neutral
activ
tendenc
second
immun
boost
neutral
antibodi
respons
benefit
third
dose
level
antibodi
respons
invers
relat
prevaccin
titer
thu
appear
safe
immunogen
rsv
seroposit
adult
follow
intramuscular
administr
structur
neuraminidas
discov
colman
catalyt
site
enzym
strain
invari
inhibitor
enzym
broad
spectrum
activ
influenza
virus
product
enzym
reaction
sialic
acid
sit
enzym
catalyt
site
high
degre
chemic
topolog
fit
except
occur
hydroxyl
sugar
insert
h
fill
caviti
protein
surfac
line
two
carboxyl
group
two
glutam
amino
acid
develop
antineuraminidas
agent
driven
observ
consider
build
basic
bulki
substitut
hydroxyl
group
might
improv
fit
site
first
two
seriou
candid
late
substitut
dehydrosial
acid
latter
known
zanamavir
varghes
et
al
small
chang
molecul
result
dramat
improv
potenc
replac
hydroxyl
amino
group
transit
ammonium
guanidinium
improv
ki
factor
approxim
case
moreov
substitut
made
compound
solubl
reduc
solubl
protein
increas
bind
constant
permit
deliveri
way
topic
attempt
replac
glycerol
side
chain
sugar
carboxamid
linkag
attach
hydrophob
substitu
methylpropyl
diethyl
side
chain
howev
substitut
result
dramat
chang
distribut
properti
zanamavir
altern
compound
oseltamivir
also
diethyl
substitut
glycerol
posit
analogu
pyranos
compound
bind
satisfactorili
activ
site
neuraminidas
hydrophil
pocket
accommod
glycerol
alreadi
hydrophob
compon
hydrophob
surfac
expos
hydocarbon
backbon
guanidinium
back
side
glycerol
interact
hydrophob
accommod
carboxamid
made
complet
also
creat
hydrophob
environ
vicin
number
resist
variant
influenza
select
zanamavir
oseltamvir
variant
ha
ha
drug
target
mutat
aris
balanc
need
maintain
bind
receptor
destruct
viru
cycl
activ
site
variant
na
seen
number
site
enzym
activ
site
glutam
site
direct
design
zanamavir
glutam
seen
mutat
resist
variant
three
differ
amino
acid
glycin
alanin
aspart
arginin
lysin
mutat
select
zanamavir
oseltamivir
laboratori
oseltamivir
clinic
studi
singl
report
case
report
mutat
arginin
result
resist
immunocompromis
child
receiv
long
term
therapi
zanamavir
na
mutat
result
local
effect
case
lysin
virtu
charg
project
far
activ
site
pocket
end
salt
link
glutam
residu
import
creat
hydrophob
pocket
glycerol
substitut
compound
resist
index
measur
show
progress
natur
substrat
result
dramat
consequ
arginin
lysin
mutat
four
amino
compound
bound
ident
wild
type
na
arginin
variant
resist
index
oseltamivir
resist
index
enter
pocket
likelihood
gener
situat
increas
drug
becom
less
similar
substrat
drug
resist
variant
one
maintain
abil
process
natur
substrat
increasingli
abl
discrimin
drug
substrat
zanamavir
less
similar
natur
substrat
part
pocket
glutam
goe
glycin
oseltamivir
therefor
relat
glutam
glycin
substitut
resist
index
higher
zanamavir
oseltamivir
one
encourag
factor
oseltamivir
resist
factor
never
import
resist
index
practic
determin
suffici
drug
site
infect
deal
breakthrough
strain
design
ligand
nanomolar
potenc
optim
mode
becom
routin
quantifi
even
rank
bind
potenc
rang
ligand
comput
howev
remain
difficult
wherea
design
pharmacolog
featur
seem
increasingli
possibl
structur
consider
direct
add
desir
group
without
alter
molecul
bind
properti
mani
drug
discov
use
method
futur
interact
na
ha
possibl
deriv
neuraminidas
inhibitor
ni
resist
viru
either
mutat
bind
site
na
mutat
ha
give
rise
decreas
bind
affin
cell
receptor
note
earlier
case
zanamavir
influenza
viru
ni
resist
aris
mutat
posit
chang
glutam
acid
glycin
occasion
alanin
aspart
acid
posit
chang
arginin
lysin
oseltamivir
mutat
select
vitro
mendel
sidwel
influenza
b
zanamavir
glutam
acid
glycin
posit
select
vitro
similar
resist
mutant
select
oseltamivir
mutat
ha
may
result
reduc
bind
affin
ha
cell
receptor
mdck
cell
larg
link
howev
human
respiratori
tract
cell
receptor
link
studi
posttreat
clinic
isol
oseltamivir
zanamivir
trial
adult
show
emerg
viru
resist
drug
uncommon
oseltamivir
treatment
studi
provid
sequenti
nasal
swab
sampl
patient
random
receiv
treatment
placebo
oseltamivir
mg
bid
mg
bid
day
primari
assay
defin
na
enzym
inhibit
phenotyp
pretreat
isol
last
viral
cultur
secondari
assay
look
chang
viral
genotyp
adequ
phenotyp
screen
avail
ha
therefor
genotyp
assay
perform
directli
swab
sampl
sensit
viral
na
inhibit
oseltamivir
activ
metabolit
assay
patient
placebo
treat
cultur
posit
patient
studi
four
hundr
fiftytwo
match
pre
post
treatment
isol
four
patient
respond
normal
treatment
harbor
resist
viru
day
posttreat
thu
incid
ni
resist
develop
approxim
patient
four
resist
virus
subtyp
three
mutat
one
novel
mutat
identifi
support
genotyp
studi
na
n
sequenc
patient
confirm
phenotyp
detect
resist
na
mutant
one
addit
case
mutat
found
genotyp
assay
group
patient
shed
viru
day
treatment
five
patient
shed
resist
viru
exhibit
clinic
deterior
clinic
isol
decreas
sensit
ni
compar
correspond
pretreat
isol
patient
two
mutant
na
genotyp
identifi
e
exhibit
reduc
infect
replic
abil
mice
ferret
ha
genotyp
n
patient
placebo
treat
fail
identifi
treatmentrel
mutat
even
virus
carri
mutant
na
random
ha
variant
found
placebo
treatment
group
similar
rate
zanamavir
clinic
trial
na
sensit
studi
perform
posttreat
isol
na
ha
sequenc
viru
subject
drug
treat
evid
drug
treatment
relat
resist
assay
howev
isol
beyond
day
assay
zanamivir
resist
influenza
bisol
mutat
na
ha
obtain
immunocompromis
infant
zanamivir
gubareva
et
al
na
mutat
posit
gave
viru
reduct
sensit
zanamavir
ha
mutat
result
decreas
bind
human
cell
mutant
less
virul
correspond
wild
type
viru
ferret
summari
resist
ni
aris
ha
na
howev
aris
readili
vitro
clinic
incid
appear
low
resist
virus
appear
attenu
least
current
oseltamivir
trial
clinic
deterior
associ
develop
resist
overal
current
studi
suggest
neuraminidas
inhibitor
encourag
resist
profil
resist
influenza
virus
neuraminidas
inhibitor
develop
result
mutat
viral
hemagglutinin
lower
affin
ha
bind
sialic
acid
receptor
mean
bound
viru
need
less
na
activ
elut
reassort
viru
obtain
coinfect
nw
g
nw
tokyo
influenza
virus
differ
two
amino
acid
nw
reassort
mutat
almost
less
sensit
zanamavir
either
parent
plaqu
reduct
assay
also
less
sensit
zanamavir
mice
tokyo
parent
viru
lower
infect
treatment
cell
purifi
na
show
na
effici
remov
receptor
nw
bound
resist
occur
na
inhibit
drug
still
retain
suffici
activ
elut
viru
thu
balanc
ha
bind
activ
na
elut
activ
viru
influenc
sensit
zanamavir
famili
ideal
environ
transmiss
influenza
within
commun
therefor
ideal
studi
antivir
drug
efficaci
order
test
efficaci
oral
oseltamivir
prevent
secondari
spread
diseas
close
contact
influenza
infect
case
random
doubl
blind
placebo
control
studi
carri
europ
canada
us
household
contact
identifi
prior
influenza
season
surveil
use
identifi
begin
outbreak
index
case
respiratori
ill
cough
coryza
identifi
oseltamivir
mg
oral
per
day
day
placebo
given
famili
contact
index
case
fortythre
percent
index
case
confirm
influenza
infect
percent
contact
treat
within
h
onset
symptom
index
case
sever
advers
event
attribut
oseltamivir
minor
advers
event
treatment
placebo
group
week
exposur
oseltamivir
reduc
incid
clinic
influenza
caus
influenza
efficaci
p
b
efficaci
compar
placebo
contact
age
infect
person
group
overal
efficaci
reduc
influenza
b
contact
household
p
b
vs
placebo
viral
shed
reduc
individu
oseltamivir
similarli
efficaci
reduc
number
case
influenza
contact
household
index
case
respiratori
ill
caus
influenza
infect
like
acquir
outsid
household
thu
post
exposur
treatment
household
contact
oseltamivir
within
h
onset
diseas
index
case
well
toler
prevent
clinic
influenza
ill
caus
influenza
b
overal
efficaci
greater
influenza
pneumonia
lead
caus
catastroph
disabl
substanti
health
care
cost
older
adult
vaccin
cost
save
hospit
rate
pneumonia
continu
rise
clinic
diagnosi
influenza
older
adult
reliabl
disabl
influenza
signific
cough
myalgia
malais
commonli
prolong
associ
confin
bed
result
rapid
loss
muscl
power
high
per
day
nurs
home
environ
outbreak
influenza
frequent
signific
morbid
mortal
despit
vaccin
rate
good
vaccin
match
chemoprophylaxi
avail
influenza
amantadin
rimantadin
major
problem
viral
resist
drug
toxic
older
peopl
limit
use
outbreak
control
neuraminidas
inhibitor
overcom
disadvantag
analysi
studi
zanamavir
mg
bid
suggest
prior
vaccin
requir
realiz
benefit
zanamavir
treatment
influenza
ill
person
year
age
older
recommend
prevent
nurs
home
outbreak
includ
staff
resid
alik
vaccin
rate
greater
desir
use
antivir
outbreak
control
day
least
day
last
proven
case
influenza
drinka
et
al
antivir
offer
ill
h
ill
develop
receiv
amantadin
rimantadin
assum
resist
occur
isol
case
requir
antivir
drug
complementari
altern
vaccin
prevent
treat
influenza
ill
prophylaxi
effect
treatment
optim
nurs
home
set
long
term
prophylaxi
antivir
might
prove
difficult
cost
side
effect
associ
drug
long
term
prophylaxi
influenza
frail
elderli
safeti
efficaci
oseltamivir
mg
daili
versu
placebo
week
studi
nurs
home
resid
multicent
doubl
blind
random
placebo
control
studi
mean
age
approxim
year
group
vaccin
influenza
prior
influenza
season
drug
safe
well
toler
side
effect
similar
group
laboratori
confirm
influenza
fever
respiratori
system
symptom
occur
subject
placebo
group
oseltamivir
group
protect
efficaci
p
receiv
vaccin
earlier
laboratori
confirm
influenza
occur
placebo
recipi
subject
treat
group
protect
efficaci
complic
influenza
diminish
oseltamivir
intent
treat
popul
subject
placebo
group
develop
complic
bronchiti
pneumonia
sinus
versu
oseltamivir
group
protect
efficaci
thu
oral
oseltamivir
effect
prevent
clinic
influenza
ill
treat
vaccin
frail
elderli
individu
protect
afford
addit
provid
vaccin
two
potenti
pandem
virus
recent
emerg
transmit
human
influenza
viru
recov
sinc
ahong
precursor
aquailhong
viru
continu
circul
bird
asia
new
virus
enter
human
popul
vaccin
avail
antivir
drug
critic
prophylaxi
therapi
vaccin
prepar
activ
metabolit
oseltamivir
inhibit
replic
influenza
virus
mdck
cell
ic
valu
rang
mm
neuraminidas
enzym
activ
virus
ic
valu
rang
nm
murin
model
viru
lethal
larger
dose
viru
requir
caus
death
oral
oseltamivir
dose
mgkg
per
day
exert
protect
efficaci
virus
infect
mice
mgkg
per
day
prevent
death
mice
infect
either
viru
viru
drug
administr
delay
h
infect
viru
oseltamivir
still
effect
oseltamivir
significantli
reduc
lung
brain
viru
titer
infect
mice
dose
low
mgkg
per
day
higher
dose
stop
replic
viru
lung
howev
dose
mgkg
per
day
reduc
lung
viral
replic
viru
zero
viru
remain
lung
tissu
resist
oral
oseltamivir
combin
rimantadin
reduc
mortal
high
challeng
viru
thu
oral
oseltamivir
reduc
lung
titer
prevent
death
mice
challeng
viru
treatment
h
challeng
prevent
viral
replic
brain
studi
done
intranas
zanamavir
result
similar
neuraminidas
inhibitor
novel
neuraminidas
inhibitor
also
develop
use
ration
drug
design
novel
cyclopentan
ring
structur
allow
extens
interact
key
residu
neuraminidas
activ
site
vitro
studi
demonstr
potent
select
activ
influenza
b
neuraminidas
ic
valu
nm
viru
growth
tissu
cultur
vitro
pretreat
mdck
cell
follow
remov
drug
supernat
appear
low
inhibitori
effect
effect
activ
observ
treatment
begun
h
post
exposur
compar
neuraminidas
inhibitor
demonstr
lower
ic
influenza
influenza
b
strain
similar
activ
oral
dose
murin
model
demonstr
efficaci
prophylaxi
treatment
infect
prophylact
regimen
use
mgkg
per
day
begun
h
prior
viru
exposur
continu
day
post
infect
bid
dose
efficaci
prevent
influenza
b
infect
mice
treatment
regimen
use
mgkg
bid
day
efficaci
mice
infect
influenza
strain
treatment
begun
within
h
infect
mice
infect
viru
even
treatment
start
h
infect
cytotox
observ
dose
mm
mdck
embryon
african
kidney
human
lung
carcinoma
cell
toxic
seen
mice
rat
singl
oral
dose
mgkg
per
day
similarli
multipl
dose
mgkg
per
day
day
show
effect
pharmacokinet
studi
human
demonstr
well
toler
oral
rout
rapidli
absorb
reach
sustain
high
plasma
concentr
h
long
half
life
termin
phase
plasma
elimin
h
mean
trough
plasma
concentr
valu
exceed
median
ic
ic
influenza
b
elimin
appear
primarili
renal
phase
clinic
studi
subject
given
exhibit
advers
event
placebo
recipi
recent
test
influenza
human
challeng
model
primari
endpoint
studi
reduct
area
curv
mean
viral
titer
time
preliminari
result
indic
signific
antivir
effect
demonstr
dose
mg
bid
mg
daili
mean
durat
viral
shed
also
reduc
particularli
higher
dose
thu
novel
neuraminidas
inhibitor
uniqu
ring
structur
show
potent
antivir
activ
influenza
b
vitro
vivo
model
well
toler
human
daili
oral
regimen
produc
signific
antivir
activ
human
challeng
model
statu
pleconaril
proteas
inhibitor
rhinovirus
common
infecti
pathogen
human
caus
approxim
acut
upper
respiratori
tract
ill
associ
sinus
otiti
media
exacerb
asthma
chronic
lung
diseas
antivir
agent
proven
valu
current
avail
intranas
interferon
protect
infect
provid
therapeut
benefit
pleconaril
drug
insert
hydrophob
pocket
picornaviru
capsid
inhibit
attach
andor
viral
uncoat
pleconaril
inhibit
replic
enterovirus
rv
serotyp
vitro
concentr
obtain
oral
administr
oral
pleconaril
appear
therapeut
benefici
adult
adolesc
viral
mening
human
volunt
given
experiment
coxsacki
viru
infect
respiratori
viru
schiff
sherwood
phase
iii
clinic
trial
determin
efficaci
pleconaril
treatment
picornaviru
respiratori
ill
conduct
adolesc
adult
least
one
respiratori
one
system
symptom
less
h
durat
hayden
et
al
treatment
mg
bid
tid
pleconaril
placebo
day
differ
occur
placebo
treatment
group
advers
event
primari
endpoint
efficaci
time
complet
resolut
five
key
respiratori
system
symptom
bid
pleconaril
group
differ
placebo
group
tid
pleconaril
reduc
median
durat
symptom
recoveri
ill
day
reduct
secondari
endpoint
total
sever
symptom
specif
individu
symptom
also
reduc
tid
treatment
group
compar
placebo
treatment
benefit
detect
within
day
treatment
result
suggest
pleconaril
reduc
symptom
respiratori
ill
due
picornaviru
infect
rhinoviru
proteas
appeal
target
antivir
activ
essenti
role
viral
replic
littl
similar
mammalian
enzym
crystal
structur
proteas
determin
activ
enzym
site
highli
conserv
proteas
inhibitor
like
activ
rhinoviru
serotyp
inhibitor
use
clinic
trial
peptidomimet
inhibitor
mean
ec
nm
rang
rhinoviru
serotyp
intranas
studi
experiment
rhinoviru
infect
suscept
adult
prophylaxi
placebo
administ
h
viru
exposur
continu
time
day
day
earli
treatment
administr
begun
h
challeng
continu
day
advers
event
mild
sever
nausea
tast
disturb
consid
relat
drug
proport
individu
shed
viru
reduc
two
group
given
prophylaxi
mean
viru
titer
area
curv
auc
shed
significantli
reduc
five
time
day
group
incid
cold
total
symptom
score
respiratori
symptom
nasal
discharg
weight
also
reduc
trend
greater
effect
receiv
drug
five
time
day
earli
treatment
studi
reduc
nasal
viral
titer
day
reduct
auc
group
highli
signific
compar
placebo
total
symptom
score
respiratori
symptom
nasal
mucu
weight
significantli
reduc
compar
placebo
respect
intranas
safe
associ
signific
antivir
effect
prevent
experiment
rv
infect
moder
ill
sever
initi
either
within
one
day
infect
glucocorticosteroid
wide
rang
antiinflammatori
immunosuppress
effect
mani
organ
system
regul
adhes
molecul
inhibit
traffic
leukocyt
site
inflamm
block
releas
tnf
alpha
macrophag
block
product
interferon
gamma
addit
depress
releas
prostaglandin
leukotrien
affect
proinflammatori
arachidon
metabolit
recent
year
increas
understand
mechan
wherebi
steroid
inhibit
inflammatori
reaction
inhibit
nuclear
factor
kappa
b
steroid
inhibit
number
inflammatori
reaction
induc
virus
infecti
diseas
societi
america
recommend
steroid
viral
respiratori
ill
croup
laryngotracheobronch
croup
caus
piv
case
metaanalysi
studi
corticosteroid
treatment
croup
conclud
corticosteroid
effect
improv
outcom
croup
given
within
h
onset
symptom
ausejino
et
al
bronchiol
prototyp
diseas
rsv
infect
corticosteroid
recommend
aap
state
scientif
basi
use
bronchiol
one
sever
studi
show
benefit
reduct
daili
symptom
sever
score
steroid
treatment
center
time
use
steroid
routin
rsv
bronchiol
howev
steroid
mainstay
therapi
children
bronchial
asthma
entiti
induc
case
viral
infect
hypothesi
block
inflammatori
cascad
use
intranas
steroid
could
affect
symptom
common
cold
prospect
random
placebo
control
studi
design
administ
intranas
fluticason
propion
treatment
placebo
otherwis
healthi
young
adult
day
begin
h
onset
puhakka
et
al
approxim
case
posit
viral
etiolog
rhinoviru
isol
case
recogniz
clinic
effect
observ
sever
common
cold
symptom
patient
treat
fluticason
propion
compar
placebo
viral
sinus
present
patient
studi
period
resolv
spontan
rv
posit
case
tendenc
reduc
incid
sinus
day
ill
fluticason
group
compar
placebo
vs
respect
puhakka
et
al
fluticason
propion
recipi
posit
rv
cultur
day
ill
compar
placebo
group
statist
signific
find
disappear
pcr
result
includ
analysi
studi
intranas
fluticason
therapi
cold
children
also
found
higher
frequenc
rhinoviru
shed
otiti
media
compar
placebo
summari
steroid
effect
treatment
croup
agre
effect
treatment
bronchiol
common
cold
appear
increas
rhinoviru
shed
futur
studi
consid
use
efficaci
combin
therapi
antivir
corticosteroid
virus
lead
caus
respiratori
infect
children
adult
major
caus
morbid
mortal
worldwid
varieti
clinic
syndrom
ill
sever
result
viral
respiratori
infect
reflect
biolog
differ
variou
virus
well
differ
host
resist
infect
one
virus
princip
caus
seriou
diseas
sinus
otiti
media
bronchiol
pneumonia
exacerb
chronic
pulmonari
condit
asthma
young
children
older
adult
underli
chronic
diseas
particular
risk
signific
morbid
infect
patient
underli
immunodefici
infect
hiv
recipi
organ
transplant
may
also
experi
seriou
ill
moreov
person
reduc
abil
respond
adequ
vaccin
epidemiolog
influenza
viru
constantli
undergo
chang
new
influenza
strain
potenti
infect
human
discov
widespread
swine
us
also
first
time
influenza
b
viru
detect
harbor
seal
europ
human
outbreak
influenza
viru
aros
infect
bird
hong
kong
clear
exampl
potenti
pandem
threat
anoth
new
influenza
viru
emerg
china
caus
diseas
chicken
two
children
hong
kong
discov
infect
ill
viru
addit
underscor
need
improv
enhanc
global
viral
surveil
recent
event
indic
need
better
train
personnel
avail
adequ
laboratori
facil
develop
pandem
prepared
plan
differ
region
world
regard
role
maintain
global
influenza
surveil
network
interpandem
period
aid
countri
pandem
prepared
provid
effect
vaccin
remain
princip
intervent
pandem
plan
howev
avail
newer
antivir
agent
effect
influenza
b
addit
current
avail
antivir
offer
possibl
treatment
select
case
use
shortterm
prophylaxi
pandem
particularli
region
world
time
develop
use
vaccin
feasibl
possibl
treat
influenza
increas
demand
virolog
diagnosi
although
viral
cultur
remain
essenti
diagnost
epidemiolog
purpos
rapid
diagnost
test
base
antigen
detect
specif
rel
sensit
identifi
influenza
b
virus
avail
use
clinic
set
genom
amplif
pcr
rtpcr
greatest
sensit
technic
demand
wide
avail
immunofluoresc
elisa
assay
new
method
diagnosi
current
show
promis
taqman
pcr
real
time
quantit
pcr
techniqu
offer
rapid
result
good
sensit
less
prone
contamin
preliminari
studi
shown
promis
result
determin
viral
load
cystic
fibrosi
patient
genom
amplif
method
also
use
studi
epidemiolog
respiratori
virus
fragment
rna
recov
form
victim
influenza
pandem
use
rtpcr
shown
presenc
avianlik
ha
na
sequenc
clear
mammalian
origin
phylogenet
suggest
influenza
viru
avian
viru
underw
mammalian
adapt
although
report
other
pantrop
neurotrop
confirm
rt
pcr
assay
organ
arm
forc
institut
patholog
usa
respiratori
virus
play
signific
role
pathogenesi
clinic
cours
outcom
upper
respiratori
tract
ill
sinus
otiti
media
respiratori
syncyti
viru
rhinoviru
parainfluenza
virus
adenoviru
import
caus
ill
children
adult
winter
month
adenovirus
also
notabl
import
caus
diseas
affect
mani
differ
organ
system
viral
replic
respiratori
tract
result
stimul
multipl
pathway
inflamm
includ
cytokin
inflammatori
mediat
lead
mucocilliari
damag
dysfunct
clinic
symptom
use
combin
antiinflammatori
antivir
interferon
therapi
benefit
treatment
rhinoviru
common
cold
benefit
demonstr
use
steroid
viral
respiratori
ill
croup
children
pleconaril
compound
inhibit
receptor
bind
picornavirus
benefici
treatment
acut
rhinoviru
infect
adult
adolesc
experiment
respiratori
coxsacki
viru
infect
volunt
proteas
inhibitor
shown
reduc
infect
sever
ill
administ
earli
cours
infect
signific
breakthrough
antivir
treatment
past
year
approv
neuraminidas
inhibitor
ni
zanamavir
oseltamivir
agent
approv
usa
mani
european
south
american
countri
treatment
influenza
b
infect
reduc
sever
durat
symptom
influenza
administ
within
first
day
ill
onset
safe
gener
well
toler
develop
resist
infrequ
resist
virus
occur
late
infect
subject
either
mutat
bind
site
na
mutat
ha
reduc
bind
affin
need
na
activ
altern
resist
may
seen
balanc
ha
bind
affin
na
elut
activ
virus
without
mutat
suffici
na
activ
remain
presenc
drug
far
clinic
deterior
associ
develop
resist
resist
virus
appear
less
virul
anim
model
two
potenti
pandem
virus
recent
emerg
influenza
inhibit
vitro
anim
ni
drug
clinic
studi
oseltamivir
shown
prevent
spread
influenza
b
household
contact
administ
exposur
ill
famili
member
also
effect
prevent
clinic
influenza
vaccin
frail
elderli
popul
administ
longterm
prophylaxi
nurs
home
set
provid
addit
protect
provid
vaccin
alon
approv
agent
prophylact
use
influenza
b
infect
occur
soon
newer
similar
compound
also
develop
novel
ni
uniqu
cyclopentan
ring
structur
show
potent
activ
influenza
b
vitro
anim
model
well
toler
shown
antivir
effect
human
challeng
studi
import
intervent
control
viral
infect
complic
prevent
immun
signific
advanc
occur
recent
develop
use
antivir
vaccin
live
attenu
coldadapt
influenza
vaccin
updat
annual
match
fda
recommend
trival
inactiv
vaccin
produc
consist
viral
titer
administ
intranas
children
adult
result
immun
vaccin
strain
drift
variant
ongo
studi
seek
determin
whether
univers
immun
young
children
coldadapt
vaccin
significantli
reduc
influenza
commun
method
improv
current
avail
inactiv
influenza
vaccin
high
risk
group
elderli
use
exposur
pandem
viru
investig
immunogen
current
avail
trival
inactiv
vaccin
enhanc
supplement
recombin
na
rna
anim
model
earli
studi
human
experiment
infect
supplement
vaccin
safe
immunogen
follow
decreas
symptomatolog
viral
shed
adjuv
influenza
vaccin
immunogen
naiv
volunt
standard
aqueou
vaccin
vaccin
augment
ctl
memori
cell
enhanc
protect
pandem
interpandem
influenza
viru
infect
product
attenu
vaccin
strain
via
revers
genet
modul
interferon
sensit
new
vaccin
option
applic
revers
genet
product
vaccin
rsv
piv
permit
genotyp
phenotyp
manipul
rel
eas
earli
result
provid
promis
new
candid
vaccin
preliminari
result
cold
adaptedtemperatur
sensit
rsv
piv
live
attenu
vaccin
young
children
indic
vaccin
safe
immunogen
popul
altern
novel
recombin
rsv
subunit
vaccin
shown
immunogen
protect
mice
safe
immunogen
rsv
seroposit
healthi
adult
parallel
studi
defin
immun
correl
rsv
diseas
factor
contribut
sever
diseas
younger
infant
ongo
identif
tcell
epitop
rsv
clarif
role
immunopathogenesi
vaccin
target
import
effort
